nVector

nVector is a private, pre-clinical stage biotech firm founded in 2016, operating at the intersection of drug delivery and viral technology. The company's primary asset is its proprietary GreenGlia™ AAV platform, featuring a library of over 10 million capsid variants engineered for superior targeting and distribution within the brain and spinal cord. In addition to its internal therapeutic pipeline targeting neurodegenerative diseases, nVector offers platform licensing and custom capsid engineering services to partners, alongside a biomarker testing and development service led by industry veterans. The company appears to be pre-revenue, focusing on platform validation and partnership development to advance its technologies and programs.

Proprietary GreenGlia™ AAV platform featuring a library of >10 million capsid variants engineered for cell-type specific targeting (glia and neurons), enhanced distribution in the CNS, and custom capsid design using computational biology tools.

nVector competes in the crowded next-generation AAV capsid engineering field against companies like 4D Molecular Therapeutics (4DMT) and Dyno Therapeutics (partnered with Roche, Novartis). Its differentiation lies in its specific claim of glial cell targeting and its integrated biomarker service offering, but it faces significant competition from larger, more capitalized players.